Mitochondrial toxicity assessment in industry-a decade of technology development and insight

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 8, 2014, Pages 1061-1067

  Will, Yvonne ^a   Dykens, James ^b  

^a PFIZER INC   (United States)

^b EyeCyte Therapeutics   (United States)

Author keywords

Drugs; Liver injury; Mitochondria; Toxicity

Indexed keywords

ADENOSINE TRIPHOSPHATE; BUFORMIN; BUSPIRONE; CERIVASTATIN; METFORMIN; PHENFORMIN; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; TROGLITAZONE;

CYTOTOXICITY TEST; HUMAN; MITOCHONDRIAL TOXICITY; MITOCHONDRION; REVIEW; ADVERSE DRUG REACTION; ANIMAL; DRUG EFFECTS; DRUG INDUSTRY; DRUG-INDUCED LIVER INJURY; LIVER MITOCHONDRION; MEDICAL TECHNOLOGY; PATHOLOGY; PROCEDURES; TRENDS;

ANIMALS; BIOMEDICAL TECHNOLOGY; DRUG INDUSTRY; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MITOCHONDRIA; MITOCHONDRIA, LIVER;

EID: 84904334374     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.939628     Document Type: Review

References (39)

1. Dimauro S, Davidzon G. Mitochondrial DNA and disease. Ann Med 2005;37:222-32
2. Tirmenstein MA, Hu CX, Gales TL, et al. Effects of troglitazone on HepG2 viability and mitochondrial function. Toxicol Sci 2002;69:131-8
3. Westwood FR, Bigley A, Randall K, et al. Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol Pathol 2005;33:246-57
4. Dykens JA, Marroquin LD, Will Y. Strategies to reduce late-stage drug attrition due to mitochondrial toxicity. Expert Rev Mol Diagn 2007;7:161-75
5. Website describing oxygraphs. Available from www.hansatech.com [Last accessed 20 June 2014]
6. Website describing high resolution respirometry. Available from www.orosboros.com [Last accessed 20 June 2014]
7. Website desribign soluble oxygen sensors. Available from www.luxcel.com [Last accessed 20 June 2014]
8. Hynes J, Marroquin LD, Ogurtsov VI, et al. Investigation of drug-induced mitochondrial toxicity using fluorescencebased oxygen-sensitive probes. Toxicol Sci 2006;92:186-200
9. Hynes J, Natoli E Jr, Will Y. Fluorescent pH and oxygen probes of the assessment of mitochondrial toxicity in isolated mitochondria and whole cells. Curr Protoc Toxicol 2009;Chapter 2:Unit 2.16
10. Hynes J, Swiss RL, Will Y. High-throughput analysis of mitochondrial oxygen consumption. Methods Mol Biol 2012;810:59-72
11. Nadanaciva S, Bernal A, Aggeler R, et al. Target identification of drug induced mitochondrial toxicity using immunocapture based OXPHOS activity assays. Toxicol In Vitro 2007;21:902-11
12. Nadanaciva S, Dykens JA, Bernal A, et al. Mitochondrial toxicity of PPAR agonists and statins is exacerbated by combined exposure. Toxicol Appl Pharmacol 2007;223:277-87
13. Halestrap AP, Price NT. The protonlinked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem J 1999;343:281-99
14. Wang DS, Kusuhara H, Kato Y, et al. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol 2003;63:844-8
15. Dykens JA, Jamieson J, Marroquin L, et al. Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro. Toxicol Appl Pharmacol 2008;233:203-10
16. Dykens JA, Jamieson JD, Marroquin LD, et al. In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol Sci 2008;103:335-45
17. Marroquin LD, Hynes J, Dykens JA, et al. Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol Sci 2007;97:539-47
18. Swiss R, Will Y. Assessment of mitochondrial toxicity in HepG2 cells cultured in high-glucose- or galactosecontaining media. Curr Protoc Toxicol 2011;Chapter 2:Unit2.20
19. Reitzer LJ, Wice BM, Kennell D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem 1979;254:2669-76
20. Hynes J, Nadanaciva S, Swiss R, et al. A high-throughput dual parameter assay for assessing drug-induced mitochondrial dysfunction provides additional predictivity over two established mitochondrial toxicity assays. Toxicol In Vitro 2013;27:560-9
21. Swiss R, Niles A, Cali JJ, et al. Validation of a HTS-amenable assay to detect drug-induced mitochondrial toxicity in the absence and presence of cell death. Toxicol In Vitro 2013;27:1789-97
22. Website describing the mitochondrial toxicity test. Available from www.promega.com [Last accessed 20 June 2014]
23. Website describing the metablic flux analyzer. Available from www.seahorsebiosciences.com [Last accessed 20 June 2014]
24. Nadanaciva S, Rana P, Beeson GC, et al. Assessment of drug-induced mitochondrial dysfunction via altered cellular respiration and acidification measured in a 96-well platform. J Bioenerg Biomembr 2012;44:421-37
25. Porceddu M, Buron N, Roussel C, et al. Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria. Toxicol Sci 2012;129:332-45
26. Aleo MD, Luo Y, Swiss R, et al. Human drug-induced liver injury severity is highly associated to dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology 2014; Epub ahead of print
27. Ong MM, Latchoumycandane C, Boelsterli UA. Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicol Sci 2007;97:205-13
28. Hsiao CJ, Younis H, Boelsterli UA. Trovafloxacin, a fluoroquinolone antibiotic with hepatotoxic potential, causes mitochondrial peroxynitrite stress in a mouse model of underlying mitochondrial dysfunction. Chem Biol Interact 2010;188:204-13
29. Pereira CV, Oliveira PJ, Will Y, Nadanaciva S. Mitochondrial bioenergetics and drug-induced toxicity in a panel of mouse embryonic fibroblasts with mitochondrial DNA single nucleotide polymorphisms. Toxicol Appl Pharmacol 2012;264:167-81
30. Amara CE, Marcinek DJ, Shankland EG, et al. Mitochondrial function in vivo: spectroscopy provides window on cellular energetics. Methods 2008;46:312-18
31. Website describing antibodies commonly used for mitochondrial research. Available from www.mitosciences.com [Last accessed 20 June 2014]
32. Naven RT, Swiss R, Klug-McLeod J, et al. The development of structureactivity relationships for mitochondrial dysfunction: uncoupling of oxidative phosphorylation. Toxicol Sci 2013;131:271-8
33. Nadanaciva S, Dillman K, Gebhard DF, et al. High-content screening for compounds that affect mtDNA-encoded protein levels in eukaryotic cells. J Biomol Screen 2010;15:937-48
34. Laifenfeld D, Qiu L, Swiss R, et al. Utilization of causal reasoning of hepatic gene expression in rats to identify molecular pathways of idiosyncratic drug-induced liver injury. Toxicol Sci 2014;137:234-48
35. McGill MR, Jaeschke H. Apoptosis or necrosis in acetaminophen-induced acute liver failure? New insights from mechanistic biomarkers. Crit Care Med 2013;41:2653-4
36. McGill MR, Cao M, Svetlov A, et al. Argininosuccinate synthetase as a plasma biomarker of liver injury after acetaminophen overdose in rodents and humans. Biomarkers 2014;19:222-30
37. Korrapati M, Whitaker RM, Stallons LJ, et al. ATP synthase beta is a novel urinary biomarker of renal mitochondrial dysfunction. Toxicologist 2014;138:25
38. Stallons LJ, Arthur J, Beeson C, Schnellmann RG. Urinary mitochondrial DNA as a novel biomarker of mitochondrial dysfunction in human acute kidney injury. Toxicologist 2014;138:24
39. Website of global provider of genetically modified mouse and rat models and services. Available from: www.taconic.com [Last accessed 25 June 2014]